🇺🇸 FDA
Patent

US 11439641

Pyrimidine JAK inhibitors for the treatment of skin diseases

granted A61KA61K31/506A61K9/06

Quick answer

US patent 11439641 (Pyrimidine JAK inhibitors for the treatment of skin diseases) held by Theravance Biopharma R&D IP, LLC expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K31/506, A61K9/06, A61P, A61P17/00